Metabolomics analysis reveals serum biomarkers in patients with diabetic sarcopenia

• Published in: Frontiers in endocrinology (Lausanne) Vol. 14; p. 1119782
• Main Authors: Tan, Yuwei, Liu, Xiaosong, Yang, Yinping, Li, Baoying, Yu, Fei, Zhao, Wenqian, Fu, Chunli, Yu, Xin, Han, Zhenxia, Cheng, Mei
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 22.03.2023
• Subjects: biomarkers; Biomarkers - blood; Biomarkers - metabolism; Cross-Sectional Studies; diabetes; Diabetes Complications - blood; Diabetes Complications - metabolism; Diabetes Complications - physiopathology; Diabetes Mellitus - blood; Diabetes Mellitus - metabolism; Diabetes Mellitus - physiopathology; Endocrinology; Glutamine; Humans; Metabolome; metabolomics; sarcopenia; Sarcopenia - blood; Sarcopenia - etiology; Sarcopenia - metabolism; Sarcopenia - physiopathology; serum metabolites; serum metabolites; metabolomics; diabetes; biomarkers; sarcopenia
• DOI: 10.3389/fendo.2023.1119782
• ISSN: 1664-2392

Diabetic sarcopenia (DS) is characterized by muscle atrophy, slower nerve conduction, reduced maximum tension generated by skeletal muscle contraction, and slower contraction rate. Hence, DS can cause limb movement degeneration, slow movement, reduced balance, reduced metabolic rate, falls, fractures, etc. Moreover, the relevant early biological metabolites and their pathophysiological mechanism have yet to be characterized. The current cross-sectional study employed serum metabolomics analysis to screen potential noninvasive biomarkers in patients with diabetic sarcopenia. A total of 280 diabetic patients were enrolled in the study (n = 39 sarcopenia [DS], n = 241 without sarcopenia [DM]). Ten patients were randomly selected from both groups. Non-targeted metabolomic analysis was performed by ultra-high-performance liquid chromatography-electrospray ionization tandem mass spectrometry. A total of 632 differential metabolites were identified, including 82 that were significantly differentially abundant ( < 0.05, VIP > 1, FC > 1.2 or FC < 0.8). Compared with the DM group, the contents of pentadecanoic acid, 5'-methylthioadenosine (5'-MTA), N,N-dimethylarginine (asymmetric dimethylarginine, ADMA), and glutamine in the DS group were significantly increased, while that of isoxanthohumol was decreased. Based on receiver operating characteristic curve analysis, pentadecanoic acid, 5'-MTA, ADMA, and glutamine may serve as potential biomarkers of DS. Moreover, ATP-binding cassette (ABC) transporters and the mammalian target of the rapamycin signaling pathway were found to potentially have important regulatory roles in the occurrence and development of DS (P < 0.05). Collectively, the differential metabolites identified in this study provide new insights into the underlying pathophysiology of DS and serve as a basis for therapeutic interventions.